Invivyd (IVVD) Q2 2024 earnings summary

Executive summary

• Leadership transition and new executive appointments aim to expand ambition, improve efficiency, and strengthen commercial operations, with a focus on delivering value to vulnerable populations at risk from respiratory viruses, especially COVID-19.

• PEMGARDA was commercially launched in Q2 2024, generating $2.3 million in initial product revenue and accelerating commercial momentum into Q3.

• Expanded commercial reach includes increased infusion center utilization, broad payer coverage, and a major activation campaign for the fall-winter respiratory season.

• Ongoing R&D efforts include advancing VYD2311 to first-in-human trials and submitting an EUA amendment for PEMGARDA for treatment of mild-to-moderate COVID-19.

• Company continues to educate stakeholders on antibody prophylaxis options and adapt to evolving virology and regulatory requirements.

Financial highlights

• Q2 2024 product revenue was $2.3 million, with net loss of $47.2 million ($0.40 per share); cash and cash equivalents totaled $147.9 million at June 30, 2024.

• Revenue guidance for 2024 is $150–$200 million, with projected year-end cash of $75 million.

• Operating efficiencies and commercial expansion began to yield benefits in Q2, with significant R&D investment in VYD2311.

• SG&A expenses rose to $21.1 million in Q2 2024, reflecting commercialization costs and increased personnel.

• Cash used in operations was $91.8 million for the first half of 2024.

Outlook and guidance

• Major commercial activation campaign is set for the fall, with digital campaigns, expanded sales force, and increased infusion site access.

• 2024 revenue guidance remains $150–$200 million, with 30–40K PEMGARDA doses expected to be sold by year-end and at least $75 million in year-end cash.

• Management anticipates continued losses and negative cash flows as commercialization and R&D expand, with additional funding to be sought if needed.

• Guidance focuses on product sales and operating contribution as primary sources of capital.

• Anticipates increased demand during the fall-winter respiratory season, with September–November as peak months.